News

The FDA has given the targeted inhibitor alrizomadlin a rare pediatric disease designation for the treatment of neuroblastoma.

Researchers found that depletion of naïve T cells from peripheral blood stem cell allografts results in very low incidences of severe acute and chronic graft-versus-host disease without reduced risk of relapse or nonrelapse mortality.

In an interview with Targeted Oncology following the tweet chat, Yelena Y. Janjigian, discussed the key takeaways from the discussion and highlighted the biomarkers and standard of care for the patient in this case.

Despite its infrequency, early cardiac toxicity may occur more often in patients who received cyclophosphamide-based graft-versus-host disease prophylaxis and those who have a prior history of cardiac disease.

Michael Wang, MD, discusses the study design of the ongoing, multicenter, open-label study examining an acalabrutinib triplet in MCL.

The FDA has issued a complete response letter denying approval of sintilimab injection in combination with pemetrexed and platinum chemotherapy as frontline treatment for patients with nonsquamous non–small cell lung cancer.

With larotrectinib treatment, patients with advanced lung cancers whose tumors harbor NTRK gene fusions experienced durable responses, survival benefit, and a favorable safety profile.

Theodore W. Laetsch, MD, discusses various trials examining larotrectinib in patients with TRK fusion positive thyroid cancer.

Findings presented during the SGO Annual Meeting show that atezolizumab given prior to concurrent chemoradiation may be safe with immune modulating activity in patients with node-positive, locally advanced cervical cancer.

Haploidentical donor-derived allogeneic hematopoietic cell transplant appears to be feasible for patients with Philadelphia chromosome-positive chronic myeloid leukemia, similar to other donor types.

Lisocabtagene maraleucel has demonstrated benefit to event-free survival for patients with relapsed/refractory large B-cell lymphoma.

Treatment locations in New York, New Jersey, and Florida are recruiting patients with mall cell lung cancer to receive olaparib and low-dose radiotherapy in a phase 1 clinical trial.

Data from the SORAYA trial shows the use of mirvetuximab soravtansine monotherapy in patients with ovarian cancer to result in meaningful anti-tumor activity, consistent safety, and favorable tolerability.

In an interview with Targeted Oncology, Charles Geyer, MD, discussed the data from the OlympiA clinical trial and how adjuvant olaparib could impact the treatment of BRCA-positive, HER2-negative breast cancer and other BRCA-positive women’s cancers.

Pembrolizumab is now an FDA-approved treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.

Solange Peters, MD, PhD, discusses the ways in which oncologists can manage toxicities in patients with unresectable malignant pleural mesothelioma.

The FDA has granted approval to the fixed-dose combination of relatlimab plus nivolumab for the treatment of adult and pediatric patients with unresectable or metastatic melanoma.

The FDA has released a draft of new recommendations for the manufacture, development, and study design of chimeric antigen receptor T cells.

Two medical oncologists become the are the latest board-certified, fellowship-trained physicians who have chosen to practice medicine at Cancer Treatment Centers of America.

Following the important information provided by the phase 3 VESPER trial, Jean Hoffman-Censits, Md said there are several noteworthy ongoing phase 3 neoadjuvant immunotherapy studies in bladder cancer.

Tafasitamab-cxi plus lenalidomide has been added to the NCCN Guidelines as a preferred regimen for patients with diffuse large B-cell lymphoma.

Orphan drug designation has been granted to TCB-002 for use as a potential therapeutic option in patients with relapsed/refractory acute myeloid leukemia.

In an interview with Targeted Oncology, Ghaith Abu-Zeinah, discussed the factors contributing to overall survival in patients with polycythemia vera and what is expected of future research.

Ming Zhao, MD, explains the background of the FOHAIC-1 study.

The FDA has approved the FoundationOne CDx as a companion diagnostic to identify patients with non–small cell lung cancer with tumors that harbor EGFR exon 19 deletions or exon 21 substitutions.

The KEYLYNK-010 trial of pembrolizumab and olaparib was terminated following negative overall survival results in patients with metastatic castration-resistant prostate cancer.

Selinexor shows statistically significant improvement in progression-free survival in patients with endometrial cancer.

In an interview with Targeted Oncology, Steven M. Albelda, MD, discussed the introduction of chimeric antigen receptor T cells in solid tumor research and how it differs from what has been observed in hematologic malignancies.

Three and a half-year follow-up in the OlympiA trial showed continued survival improvement and underscores the vitality of germline BRCA testing.